SOURCE: Eugene Science, Inc.

November 28, 2007 08:00 ET

Eugene Science Expands Global Operations

Opens U.S. Office to Service Growing Business in the Americas and Europe

LOS ANGELES, CA--(Marketwire - November 28, 2007) - Eugene Science Inc. (OTCBB: EUSI), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ™) plant sterols, today announced it has opened a U.S. headquarters office in Los Angeles. The new office will support sales and marketing in North America, Latin America and Europe. The Company's Asian markets will continue to be served through the Company's corporate offices in Seoul, Korea.

Eugene Science is in the process of launching a number of new sales and marketing initiatives in both North and South America and is experiencing strong traction with its new business development in both regions. Establishing the new office will advance the Company's global expansion plans and reflects management's commitment to providing current and new customers with excellent service and support.

Address and phones:
Eugene Science, U.S.A
3699 Wilshire Blvd
Suite 700-03
Los Angeles, CA  90010
Tel: 213-384-5008

To be added to Eugene Science's investor lists, please contact Zachary Bryant at or at 818-382-9718.

About Eugene Science, Inc.

Based in Seoul, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-dispersible functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit

Forward-Looking Statements: This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at, press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, the willingness of Eugene Science's creditors to enter into restructuring and workout agreements with respect to its outstanding debt, and the availability of adequate working capital to continue Eugene Science's operations. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Investor Relations International
    Zachary Bryant
    Senior Vice President and Account Group Manager
    Email Contact